The ACCENT Phase 2 Clinical Trial (AMP945-PC-201) has strict entry criteria. Please note, Amplia is not recruiting patients directly and all enquiries for involvement must be made via our partnering clinical trial sites.
- The trial is now open for recruitment.
- Clinical trial sites are located in Brisbane, Sydney and Melbourne, Australia.
- The ACCENT trial will test if AMP945 helps people with pancreatic cancer have a better response to standard of care chemotherapies, gemcitabine and nab-paclitaxel.
- AMP945 aims to break down the fibrotic tissue shield in pancreatic cancer to allow the chemotherapy to better penetrate the cells be more effective.